Landmark physical characterization of cancer cells completed

An enormous collaborative effort between a multitude of academic and research centers has characterized numerous physical and mechanical properties on one identical human cancer cell line. Their two-year cooperative study, published online in the April 26, 2013 journal Science Reports, reveals the persistent and agile nature of human cancer cells as compared to noncancerous cells. It also represents a major shift in the way scientific research can be accomplished.

Human breast cancer cells like these were used in the study. (Image created by Shyam Khatau/ Wirtz Lab)

Human breast cancer cells like these were used in the study. (Image created by Shyam Khatau/ Wirtz Lab)

The research, which was conducted by 12 federally funded Physical Sciences-Oncology Centers (PS-OC) sponsored by the National Cancer Institute, is a systematic comparison of metastatic human breast-cancer cells to nonmetastatic breast cells that reveals dramatic differences between the two cell lines in their mechanics, migration, oxygen response, protein production and ability to stick to surfaces. They have also discovered new insights into how human cells make the transition from nonmalignant to metastatic, a process that is not well understood.

Denis Wirtz, a Johns Hopkins professor of chemical and biomolecular engineering with joint appointments in pathology and oncology who is the corresponding author on the study, remarked that the work adds a tremendous amount of information about the physical nature of cancer cells. “For the first time ever, scientists got together and have created THE phenotypic signature of cancer” Wirtz said. “Yes, it was just one metastatic cell line, and it will require validation with many other cell lines. But we now have an extremely rich signature containing many parameters that are distinct when looking at metastatic and nonmetastatic cells.”

Wirtz, who directs the Johns Hopkins Physical Sciences-Oncology Center, also noted the unique way in which this work was conducted: all centers used the same human cell line for their studies, which makes the quality of the results unparalleled. And, since human and not animal cells were used, the findings are immediately relevant to the development of drugs for the treatment of human disease.

“Cancer cells may nominally be derived from the same patient, but in actuality they will be quite different because cells drift genetically over just a few passages,” Wirtz said.  “This makes any measurement on them from different labs like comparing apples and oranges.” In this study, however, the genetic integrity of the cell lines were safeguarded by limiting the number times the original cell cultures could be regrown before they were discarded.

The nationwide PS-OC brings together researchers from physics, engineering, computer science, cancer biology and chemistry to solve problems in cancer, said Nastaran Zahir Kuhn, PS-OC program manager at the National Cancer Institute.

“The PS-OC program aims to bring physical sciences tools and perspectives into cancer research,” Kuhn said. “The results of this study demonstrate the utility of such an approach, particularly when studies are conducted in a standardized manner from the beginning.”

For the nationwide project, nearly 100 investigators from 20 institutions and laboratories conducted their experiments using the same two cell lines, reagents and protocols to assure that results could be compared. The experimental methods ranged from physical measurements of how the cells push on surrounding cells to measurements of gene and protein expression.

“Roughly 20 techniques were used to study the cell lines, enabling identification of a number of unique relationships between observations,” Kuhn said.

Wirtz added that it would have been logistically impossible for a single institution to employ all of these different techniques and to measure all of these different parameters on just one identical cell line. That means that this work accomplished in just two years what might have otherwise taken ten, he said.

The Johns Hopkins PS-OC made specific contributions to this work. Using particle-tracking microrheology, in which nanospheres are embedded in the cell’s cytoplasm and random cell movement is visually monitored, they measured the mechanical properties of cancerous versus noncancerous cells. They found that highly metastatic breast cancer cells were mechanically softer and more compliant than cells of less metastatic potential.

Using 3D cell culturing techniques, they analyzed the spontaneous migratory potential (that is, migration without the stimulus of any chemical signal) of cancerous versus noncancerous cells. They also analyzed the extracellular matrix molecules that were deposited by the two cell lines and found that cancerous cells deposited more hyaluronic acid (HA). The HA, in turn, affects motility, polarization and differentiation of cells.  Finally, the Hopkins team measured the level of expression of CD44, a cell surface receptor that recognizes HA, and found that metastatic cells express more CD44.

The next steps, Wirtz said, would be to validate these results using other metastatic cell lines.  To read the paper, which is published in an open access journal, follow this link: http://www.nature.com/srep/2013/130422/srep01449/full/srep01449.html

Excerpts from original press release by Princeton science writer Morgan Kelly were used.

 

 

 

 

Recent publications from the Johns Hopkins Physical Sciences-Oncology Center

Johns Hopkins Physical Sciences-Oncology Center has had a productive quarter publishing from February to May 2013. Here are some of the most recent publications in support or the center’s core research projects, including a huge collaborative work drawing on the knowledge and research findings of the entire PS-OC network.

Screen Shot 2013-05-15 at 4.27.37 PMThat paper, A physical sciences network characterization of non-tumorigenic and metastatic cells, was the work of 95 authors from all 12 of the National Cancer Institute’s PS-OC  program centers. JHU’s PS-OC director Denis Wirtz, the Theophilus H. Smoot Professor in the Johns Hopkins Department of Chemical and Ciomolecular Engineering, is the corresponding author on this massive effort. We will be discussing the findings of that paper in a future post here on the PS-OC website. Until then, here is a link to that network paper and 13 other recent publications from the Johns Hopkins PS-OC.

  • A physical sciences network characterization of non-tumorigenic and metastatic cells.Physical Sciences – Oncology Centers Network, Agus DB, Alexander JF, Arap W,Ashili S, Aslan JE, Austin RH, Backman V, Bethel KJ, Bonneau R, Chen WC,Chen-Tanyolac C, Choi NC, Curley SA, Dallas M, Damania D, Davies PC, Decuzzi P,Dickinson L, Estevez-Salmeron L, Estrella V, Ferrari M, Fischbach C, Foo J,Fraley SI, Frantz C, Fuhrmann A, Gascard P, Gatenby RA, Geng Y, Gerecht S,Gillies RJ, Godin B, Grady WM, Greenfield A, Hemphill C, Hempstead BL, HielscherA, Hillis WD, Holland EC, Ibrahim-Hashim A, Jacks T, Johnson RH, Joo A, Katz JE,Kelbauskas L, Kesselman C, King MR, Konstantopoulos K, Kraning-Rush CM, Kuhn P,Kung K, Kwee B, Lakins JN, Lambert G, Liao D, Licht JD, Liphardt JT, Liu L, LloydMC, Lyubimova A, Mallick P, Marko J, McCarty OJ, Meldrum DR, Michor F,Mumenthaler SM, Nandakumar V, O’Halloran TV, Oh S, Pasqualini R, Paszek MJ,Philips KG, Poultney CS, Rana K, Reinhart-King CA, Ros R, Semenza GL, Senechal P,Shuler ML, Srinivasan S, Staunton JR, Stypula Y, Subramanian H, Tlsty TD, TormoenGW, Tseng Y, van Oudenaarden A, Verbridge SS, Wan JC, Weaver VM, Widom J, Will C, Wirtz D, Wojtkowiak J, Wu PH.  Sci Rep. 2013 Apr 25;3:1449. doi:10.1038/srep01449. PubMed PMID: 23618955; PubMed Central PMCID: PMC3636513. http://www.ncbi.nlm.nih.gov/pubmed/23618955
  • Procollagen Lysyl Hydroxylase 2 Is Essential for Hypoxia-Induced Breast Cancer Metastasis. Gilkes DM, Bajpai S, Wong CC, Chaturvedi P, Hubbi ME, Wirtz D, Semenza GL.Mol Cancer Res. 2013 May 7. [Epub ahead of print] PubMed PMID: 23378577. http://www.ncbi.nlm.nih.gov/pubmed/23378577
  • Predicting how cells spread and migrate: Focal adhesion size does matter. Kim DH, Wirtz D. Cell Adh Migr. 2013 Apr 29;7(3). [Epub ahead of print] PubMed PMID: 23628962. http://www.ncbi.nlm.nih.gov/pubmed/23628962
  • Hypoxia-inducible Factor 1 (HIF-1) Promotes Extracellular Matrix Remodeling under Hypoxic Conditions by Inducing P4HA1, P4HA2, and PLOD2 Expression in Fibroblasts. Gilkes DM, Bajpai S, Chaturvedi P, Wirtz D, Semenza GL. J Biol   Chem. 2013 Apr 12;288(15):10819-29. doi: 10.1074/jbc.M112.442939. Epub 2013 Feb 19. PubMed PMID: 23423382; PubMed Central PMCID: PMC3624462. http://www.ncbi.nlm.nih.gov/pubmed/23423382
  • Perivascular cells in blood vessel regeneration. Wanjare M, Kusuma S, Gerecht S. Biotechnol J. 2013 Apr;8(4):434-47. doi: 10.1002/biot.201200199. PubMed PMID: 23554249. http://www.ncbi.nlm.nih.gov/pubmed/23554249
  • Focal adhesion size uniquely predicts cell migration. Kim DH, Wirtz D. FASEB J. 2013 Apr;27(4):1351-61. doi: 10.1096/fj.12-220160. Epub 2012 Dec 19. PubMed PMID: 23254340; PubMed Central PMCID: PMC3606534. http://www.ncbi.nlm.nih.gov/pubmed/23254340
  • Notch4-dependent Antagonism of Canonical TGFβ1  Signaling Defines Unique Temporal Fluctuations of SMAD3 Activity in Sheared Proximal Tubular Epithelial Cells. Grabias BM, Konstantopoulos K. Am J Physiol Renal Physiol. 2013 Apr 10. [Epub ahead of print] PubMed PMID: 23576639. http://www.ncbi.nlm.nih.gov/pubmed/23576639
  • Integration and regression of implanted engineered human vascular networks during deep wound healing. Hanjaya-Putra D, Shen YI, Wilson A, Fox-Talbot K, Khetan S, Burdick JA, Steenbergen C, Gerecht S. Stem Cells Transl Med. 2013 Apr;2(4):297-306. doi: 10.5966/sctm.2012-0111. Epub 2013 Mar 13. PubMed PMID: 23486832. http://www.ncbi.nlm.nih.gov/pubmed/23486832
  • Collagen Prolyl Hydroxylases are Essential for Breast Cancer Metastasis. Gilkes DM, Chaturvedi P, Bajpai S, Wong CC, Wei H, Pitcairn S, Hubbi ME, Wirtz D, Semenza GL. Cancer Res. 2013 Mar 28. [Epub ahead of print] PubMed PMID: 23539444. http://www.ncbi.nlm.nih.gov/pubmed/23539444
  • Simultaneously defining cell phenotypes, cell cycle, and chromatin modifications at single-cell resolution.Chambliss AB, Wu PH, Chen WC, Sun SX, Wirtz D.FASEB J. 2013 Mar 28. [Epub ahead of print] PubMed PMID: 23538711.http://www.ncbi.nlm.nih.gov/pubmed/23538711
  • Interstitial friction greatly impacts membrane mechanics. Wirtz D. Biophys J.2013 Mar 19;104(6):1217-8. doi: 10.1016/j.bpj.2013.02.003. Epub 2013 Mar 19.PubMed PMID: 23528079; PubMed Central PMCID: PMC3602747.http://www.ncbi.nlm.nih.gov/pubmed/23528079
  • Functional interplay between the cell cycle and cell phenotypes. Chen WC, Wu PH, Phillip JM, Khatau SB, Choi JM, Dallas MR, Konstantopoulos K,Sun SX, Lee JS, Hodzic D, Wirtz D.Integr Biol (Camb). 2013 Mar;5(3):523-34. doi:10.1039/c2ib20246h. PubMed PMID: 23319145 http://www.ncbi.nlm.nih.gov/pubmed/23319145
  • High-throughput secretomic analysis of single cells to assess functional cellular heterogeneity. Lu Y, Chen JJ, Mu L, Xue Q, Wu Y, Wu PH, Li J, Vortmeyer AO, Miller-Jensen K, Wirtz D, Fan R. Anal Chem. 2013 Feb 19;85(4):2548-56. doi:10.1021/ac400082e. Epub 2013 Feb 1. PubMed PMID: 23339603; PubMed Central PMCID:  PMC3589817.http://www.ncbi.nlm.nih.gov/pubmed/23339603

 

Microscopic grippers used successfully in animal biopsies

Tiny, untethered microscale grippers have been successfully used to perform tissue biopsies in live animals, a study in the journal Gastroenterology reports. Researchers affiliated with the Johns Hopkins School of Medicine, Whiting School of Engineering and Institute for NanoBiotechnology developed the self-assembling microgrippers, called mu-grippers. The star-shaped devices use the animal’s own body heat to trigger them to clamp down around tissue to grab a sample like a tiny hand. Because the grippers are magnetic, they can later be retrieved for a minimally invasive procedure.

Dozens of dust-sized surgical mu- grippers in a vial. (Photo by  Evin Gultepe, Gracias Lab, Johns Hopkins University)

Dozens of dust-sized surgical mu- grippers in a vial. (Photo by Evin Gultepe, Gracias Lab, Johns Hopkins University)

David Gracias, the principal investigator for the study and associate professor of chemical and biomolecular engineering, was quoted in a Johns Hopkins press release about the work: ”This is the first time that anyone has used a sub-millimeter-sized device — the size of a dust particle — to conduct a biopsy in a live animal … That’s a significant accomplishment. And because we can send the grippers in through natural orifices, it is an important advance in minimally invasive treatment and a step toward the ultimate goal of making surgical procedures noninvasive.”

Read more here.

 

Regenerative medicine theme of science-writer bootcamp

Screen Shot 2013-04-01 at 3.19.05 PMJohns Hopkins invites you to the fifth annual science-writer boot camp. This year’s topic will be Regenerative Medicine. Join Johns Hopkins experts in regenerative medicine to learn the latest in stem cell research, tissue regeneration and organ transplantation.

Three of the 11 presenters are affiliated faculty members of the Johns Hopkins Institute for NanoBioTechnology. This event is sponsored by the Johns Hopkins Institute for Basic Biomedical Sciences.  There is no cost but reservations are required. Working press as well as freelance writers are invited to attend.

WHAT: Body Building: Recent Advances in Regenerative Medicine

WHEN: Monday, April 29, 2011, 9 a.m. to 4 p.m. (lunch will be provided)

WHERE: Bernstein-Offit Building, room LL7, Johns Hopkins SAIS Campus, 1717 Massachusetts Ave., NW, Washington, D.C. 20036

RSVP: Vanessa McMains at vmcmain1@jhmi.edu or 410-502-9410 by April 19

Confirmed speakers:

  • Gerald Brandacher, M.D. Scientific Director, Composite Tissue Allotransplantation (Reconstructive Transplant) Program
  • Robert Brodsky, M.D. Director, Division of Hematology
  • Jeff Bulte, Ph.D. Director, Cellular Imaging Section, Institute for Cell Engineering (INBT affiliated faculty)
  • Mark Donowitz, M.D. Director, Center for Epithelial Disorders; Director, Conte GI Core Research Center
  • Gary Gerstenblith, M.D. Professor, Medicine
  • Warren Grayson, Ph.D. Assistant Professor, Biomedical Engineering (INBT affiliated faculty)
  • Jun Liu, Ph.D. Professor, Pharmacology and Molecular Sciences
  • Erika Matunis, Ph.D. Associate Professor, Cell Biology
  • Guo-li Ming, M.D., Ph.D. Professor, Neurology and member of the Institute for Cell Engineering (INBT affiliated faculty)
  • Ronald Schnaar, Ph.D. Professor, Pharmacology and Molecular Sciences; Director, Lung Inflammatory Disease Program of Excellence in Glycoscience

We look forward to seeing you on April 29!

Download the color flyer here.

 

Spring nano-bio mini-symposium set for April 3

Catch up on the latest research happening in Johns Hopkins University labs working in nanobiotechnology, the physics of cancer and cancer nanotech at INBT’s spring mini-symposium Wednesday, April 3 from 9 a.m. to 1 p.m. in Leverings’s Great Hall on the Homewood campus.

AT AT GLANCE- INBT new signSMALL

Mini-symposiums are organized in the spring and fall by student leaders in the Johns Hopkins Institute for NanoBioTechnology, the Engineering in Oncology Center and the Center of Cancer Nanotechnology Excellence. They are a means of showcasing current work, learning from guest speakers and facilitating communication and collaboration among affiliated laboratories. This event is open to the entire Johns Hopkins Community. Save the date!

The agenda is as follows:

  • 9:00 am ~ 9:10 am Welcome speech Denis Wirtz, PhD, Director of Johns Hopkins Physical Science Oncology Center (PS-OC)
  • 9:10 am ~ 9:40 am “Role of ion channels and aquaporins in cancer cell migration in confined microenvironments” Kimberly M. Stroka, PhD, Postdoc fellow (PS-OC) Department of Chemical and Biomolecular Engineering, Johns Hopkins University
  • 9:40 am ~ 10:10 am “TBD” Helena Zec, Graduate student (CCNE) Department of Biomedical Engineering, Johns Hopkins University
  • 10:10 am ~ 10:40 am “Single-cell protein profiling to study cancer cell heterogeneity” Jonathan Chen, Graduate student (PS-OC) Department of Biomedical Engineering, Yale University
  • 10:40 am ~ 11:30 am “Synthetic cell biology: total synthesis of cellular functions” Takanari Inoue, PhD, Assistant professor Department of Cell Biology, Johns Hopkins University School of Medicine
  • 11:30 am ~ 11:40 am Coffee Break
  • 11:40 am ~ 12:10 pm “TBD” Yu-Ja Huang, Graduate student (PS-OC) Department of Materials Science and Engineering, Johns Hopkins University
  • 12:10 pm ~ 1:00 pm “Infections, Chronic Inflammation, and Prostate Cancer” Karen Sandell Sfanos, PhD, Assistant professor Department of Pathology, Johns Hopkins University School of Medicine
  • 1:00 pm ~ 1:30 pm “Development of CEST liposomes for monitoring nanoparticle-based cancer therapies using MRI” Tao Yu, Graduate student (CCNE) Department of Biomedical Engineering, Johns Hopkins University

INBT Spring mini-symposium flyer

Self-assembling drug molecules could fight cancer

A popular method of targeted drug delivery for anti-cancer drugs involves doping another material with the desired pharmaceutical to obtain better targeting efficiency to tumor sites. The problem with this method, researchers have discovered, is that the quantity of drug payload per delivery unit can vary widely and that the materials used for delivery can have toxic side effects.

But what if you could turn the drug molecule itself into a nanoscale delivery system, cutting out the middleman completely?

TEM image of nanotubes formed by self-assembly of an anticancer drug amphiphile. These nanotubes possess a fixed drug loading of 38% (w/w). Image from Cui Lab.

TEM image of nanotubes formed by self-assembly of an anticancer drug amphiphile. These nanotubes possess a fixed drug loading of 38% (w/w). Image from Cui Lab.

Using the process of molecular self-assembly, that is what Honggang Cui, an assistant professor in the Department of Chemical and Biomolecular Engineering at Johns Hopkins University, is attempting to do. His efforts have netted him the prestigious Faculty Early Career Development (CAREER) Award from the National Science Foundation. Cui, an affiliated faculty member of the Johns Hopkins Institute for NanoBioTechnology, will receive the $500,000 award over five years.

Cui explained that a current method of delivering anti-cancer drugs is to enclose them in a nanoscale carrier made of natural or synthetic materials, but this method presents several challenges. “The amount of drug loaded per carrier is very much limited and varies from batch to batch. Even in the same batch, there is a drug loading variation from carrier to carrier. Additionally, the carrier material itself may have toxic side effects,” he said.

Cui’s research seeks to eliminate the need for the carrier by coaxing the drug molecules themselves to form their own carrier through the process of self-assembly. His team is developing new molecular engineering strategies to assemble anti-cancer drugs into supramolecular nanostructures.

“Such supramolecules could carry as much as 100 percent of the drug, would possess a fixed amount of drug per nanostructure and would minimize the potential toxicity of the carrier,” Cui said.

To learn more about research in the Cui lab go to http://www.jhu.edu/cui/

 

FLC event focuses on Maryland technology

Screen Shot 2013-02-04 at 10.59.42 AMMaryland Technology Past, Present and Future is the topic of a day-long symposium, February 28 at the National Electronics Museum hosted by the Federal Laboratory Consortium Mid-Atlantic Region.

The FLC is a national organization chartered by Congress to foster technology transfer from federal research laboratories and field centers, to other federal agencies; state and local government; academia and the private sector. One of the regional consortium’s efforts has been to conduct a series of one-day forums that highlight specific areas of technology and encourage collaboration and partnership development with federal labs.

Registration is $25 and includes refreshments and lunch. Registration deadline is February 15 and can be made online at this link.

The National Electronics Museum is located at 1745 West Nursery Road in Linthicum, Md. The symposium begins with registration at 8:15 a.m. and adjourns at 3:45 p.m.

In addition to the presentations, the day will offer the opportunity to meet scientists from the regions National Labs such as NASA, NIST, NIH and Goddard as well as representatives of local industry. In addition to the FLC Mid-Atlantic Region, participating organizations for this symposium include Johns Hopkins University and TEDCO.

For further information or if you have difficulty accessing the registration site, please contact John Emond at 301-384-2809 or johnlamaremond@aol.com. You may also contact INBT’s director of corporate partnerships, Tom Fekete at 410-516-8891 or tmfeke@jhu.edu.

A flyer and agenda for the event are below:

Maryland Technology Day Agenda

Maryland Technology Day Flyer

INBT engineers coax stem cells to diversify

Growing new blood vessels in the lab is a tough challenge, but a Johns Hopkins engineering team has solved a major stumbling block: how to prod stem cells to become two different types of tissue that are needed to build tiny networks of veins and arteries.

The team’s solution is detailed in an article appearing in the January 2013 print edition of the journal Cardiovascular Research. The article also was published recently in the journal’s online edition. The work is important because networks of new blood vessels, assembled in the lab for transplanting into patients, could be a boon to people whose circulatory systems have been damaged by heart disease, diabetes and other illnesses.

blood-vessel-3-72

Illustration by Maureen Wanjare

“That’s our long-term goal—to give doctors a new tool to treat patients who have problems in the pipelines that carry blood through their bodies,” said Sharon Gerecht, an assistant professor of chemical and biomolecular engineering who led the research team. “Finding out how to steer these stem cells into becoming critical building blocks to make these blood vessel networks is an important step.”

In the new research paper, the Gerecht team focused on vascular smooth muscle cells, which are found within the walls of blood vessels. Two types have been identified: synthetic smooth muscle cells, which migrate through the surrounding tissue, continue to divide and help support the newly formed blood vessels; and contractile smooth muscles cells, which remain in place, stabilize the growth of new blood vessels and help them maintain proper blood pressure.

To produce these smooth muscle cells, Gerecht’s lab has been experimenting with both National Institutes of Health-approved human embryonic stem cells and induced pluripotent stem cells. The induced pluripotent stem cells are adult cells that have been genetically reprogrammed to act like embryonic stem cells. Stem cells are used in this research because they possess the potential to transform into specific types of cells needed by particular organs within the body.

In an earlier study supervised by Gerecht, her team was able to coax stem cells to become a type of tissue that resembled smooth muscle cells but didn’t quite behave properly. In the new experiments, the researchers tried adding various concentrations of growth factor and serum to the previous cells. Growth factor is the “food’ that the cells consume; serum is a liquid component that contains blood cells.

“When we added more of the growth factor and serum, the stem cells turned into synthetic smooth muscle cells,” Gerecht said. “When we provided a much smaller amount of these materials, they became contractile smooth muscles cells.”

This ability to control the type of smooth muscle cells formed in the lab could be critical in developing new blood vessel networks, she said. “When we’re building a pipeline to carry blood, you need the contractile cells to provide structure and stability,” she added. “But in working with very small blood vessels, the migrating synthetic cells can be more useful.”

In cancer, small blood vessels are formed to nourish the growing tumor. The current work could also help researchers understand how blood vessels are stabilized in tumors, which could be useful in the treatment of cancer.

“We still have a lot more research to do before we can build complete new blood vessel networks in the lab,” Gerecht said, “but our progress in controlling the fate of these stem cells appears to be a big step in the right direction.”

In addition to her faculty appointment with Johns Hopkins’ Whiting School of Engineering, Gerecht is affiliated with the university’s Institute for NanoBioTechnology (INBT) and the Johns Hopkins Engineering in Oncology Center.

The lead author of the new Cardiovascular Research paper is Maureen Wanjare, a doctoral student in Gerecht’s lab who is supported both by the INBT, through a National Science Foundation Integrative Graduate Education and Research Traineeship, and by the NIH. Coauthors of the study are Gerecht and Frederick Kuo, who participated in the research as an undergraduate majoring in chemical and biomolecular engineering. The human induced pluripotent stem cells used in the study were provided by Linzhao Cheng, a hematology professor in the Johns Hopkins School of Medicine.

This research was supported by an American Heart Association Scientist Development Grant and NIH grant R01HL107938.

Original press release can be found here.

 

Molecular culprit linked to breast cancer spread

Johns Hopkins researchers have uncovered a protein “partner” commonly used by breast cancer cells to unlock genes needed for spreading the disease around the body. A report on the discovery, published Nov. 5 on the website of the Proceedings of the National Academy of Sciences, details how some tumors get the tools they need to metastasize.

“We’ve identified a protein that wasn’t known before to be involved in breast cancer progression,” says Gregg Semenza, M.D., Ph.D., the C. Michael Armstrong Professor of Medicine at the Johns Hopkins University School of Medicine and director of the Vascular Program at the university’s Institute for Cell Engineering. “The protein JMJD2C is the key that opens up a whole suite of genes needed for tumors to grow and metastasize, so it represents a potential target for cancer drug development.” Semenza also is associate director of the Johns Hopkins Physical Sciences-Oncology Center.

Semenza and his colleagues made their finding when they traced the activity of HIF-1, a protein known to switch on hundreds of genes involved in development, red blood cell production, and metabolism in normal cells. Previous studies had shown that HIF-1 could also be hijacked to switch on genes needed to make breast tumors more malignant.

Would-be tumor cells face a host of challenges as they make the transition from working with their host to working against it, such as the need to evade the immune system and to produce more cancer cells, explains Weibo Luo, Ph.D., an instructor in the Institute for Cell Engineering and Department of Biological Chemistry who led the project. All of these efforts require switching on the right genes for the job.

To learn more about how HIF-1 works, the researchers tested a range of human proteins to see whether they would interact with HIF-1. They then sifted through the 200 resulting hits, looking for proteins involved in chemical changes to sections of DNA that determine whether or not the genes they contain are available for use. “In order for HIF-1 to switch genes on, they have to be available, but many of the genes HIF-1 activates are normally locked down in mature cells,” explains Luo. “So we thought HIF-1 must have a partner that can do the unlocking.”

That partner turned out to be JMJD2C, Luo says. Delving deeper, the researchers found that HIF-1 switches on the JMJD2C gene, stimulating production of the protein. HIF-1′s presence also enables JMJD2C to bind to DNA at other HIF-1 target genes, and then loosen those DNA sections, enabling more HIF-1 to bind to the same sites and activate the target genes.

To test the implications of their discovery, the research team injected mice with breast cancer cells in which the JMJD2C protein was not produced. Tumors with depleted JMJD2C were much less likely to grow and metastasize to the lungs, confirming the protein’s role in breast cancer progression, says Luo.

“Active HIF proteins have been found in many types of tumors, so the implications of this finding go beyond breast cancer,” says Luo. “JMJD2C is both an important piece of the puzzle of how tumors metastasize, and a potential target for anti-cancer therapy.”

Other authors of the research report are Ryan Chang, Jun Zhong, Ph.D., and Akhilesh Pandey, M.D., Ph.D., all of the Johns Hopkins University School of Medicine.

This work was supported by grants from the National Heart, Lung, and Blood Institute (contracts N01-HV28180 and HHS-N268201000032C), and by funds from the Johns Hopkins Institute for Cell Engineering.

On the Web:

Johns Hopkins Physical Sciences-Oncology Center: http://psoc.inbt.jhu.edu/

Link to article: http://www.pnas.org/content/early/2012/10/31/1217394109.abstract

Semenza lab: http://www.hopkinsmedicine.org/institute_cell_engineering/experts/gregg_semenza.html

Q&A with Semenza: http://www.hopkinsmedicine.org/institute_cell_engineering/experts/meet_scientists/gregg_semenza.html

Original press release by Shawna WilliamsCatherine Kolf and Vanessa McMains

 

 

RNA nanotechnology and therapeutics conference registration opens

Mark your calendar. Those affiliated with Johns Hopkins Institute for NanoBioTechnology or Center for Cancer Nanotechnology Excellence may be interested to know that online registration is now open for the 2013 International Conference of RNA Nanotechnology and Therapeutics to be held in Lexington, KY on April 3-5, 2013 at the Crowne Plaza Hotel & Resorts.  The meeting is organized by Peixuan Guo (University of Kentucky CNPP), John Rossi (Beckman Research Institute), Bruce Shapiro (NCI), and Neocles Leontis (Bowling Green State University). Along with invited speakers, there will also be a poster session. Invited speakers are yet to be announced.

Program topics include:

  •  Biophysical and Single Molecule Approaches in RNA Nanotechnology
  • RNA Structure and Folding in Nanoparticles
  • RNA Computation and Modeling
  • RNA Nanoparticle Assembly
  • RNA Nanoparticles in Therapeutics
  • RNA Chemistry for Synthesis, Conjugation, & Labeling of Nanoparticles
  • RNA Systems Biology and Engineering
  • Exosomes and Extracellular RNA Communication

Additional details and registration information can be found at http://nanobio.uky.edu/RNA2013